Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-27T23:51:56.603Z Has data issue: false hasContentIssue false
  • English
  • Français

Rare problems associated with the Fontan circulation

Published online by Cambridge University Press:  01 December 2010

David J. Goldberg ,
Kathryn Dodds  and
Jack Rychik
David J. Goldberg*
Affiliation:
Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
Kathryn Dodds
Affiliation:
Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
Jack Rychik
Affiliation:
Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America
*
Correspondence to: D. J. Goldberg, MD, Division of Cardiology, The Children’s Hospital of Philadelphia, 34th and Civic Center Boulevard, Philadelphia, Pennsylvania 19104, United States of America. Tel: 267 426 3058; Fax: 215 590 3267; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The Fontan operation, originally described for the surgical management of tricuspid atresia, is now the final surgery in the strategy of staged palliation for a number of different forms of congenital cardiac disease with a functionally univentricular heart. Despite the improved technical outcomes of the Fontan operation, staged palliation does not recreate a normal physiology. Without a pumping chamber delivering blood to the lungs, the cardiovascular system is less efficient; cardiac output is generally diminished, and the systemic venous pressure is increased. As a result, patients with “Fontan physiology” may face a number of rare but potentially life-threatening complications including hepatic dysfunction, abnormalities of coagulation, protein-losing enteropathy, and plastic bronchitis. Despite the staged palliation resulting in remarkable survival, the possible complications for this group of patients are complex, involve multiple organ systems, and can be life threatening. Identifying the mechanisms associated with each of the rare complications, and developing strategies to treat them, requires the work of many people at many institutions. Continued collaboration between sub-specialists and between institutions will be required to optimise the care for this group of survivors with functionally univentricular hearts.

Keywords

Congenital heart diseasepaediatric cardiac diseasehepatic dysfunctionabnormalities of coagulationprotein-losing enteropathyplastic bronchitissingle ventriclefunctionally univentricular heart
Type
Original Article
Information
Cardiology in the Young , Volume 20 , Issue S3: Rare and Challenging Congenital Cardiac Lesions: an Interdisciplinary Approach , December 2010 , pp. 113 - 119
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Fontan, F, Baudet, E. Surgical repair of tricuspid atresia. Thorax 1971; 26: 240–248.CrossRefGoogle ScholarPubMed
2.Kreutzer, G, Galindez, E, Bono, H, De Palma, C, Laura, JP. An operation for the correction of tricuspid atresia. J Thorac Cardiovasc Surg 1973; 66: 613–621.CrossRefGoogle ScholarPubMed
3.Kim, SJ, Kim, WH, Lim, HG, Lee, JY. Outcome of 200 patients after an extracardiac Fontan procedure. J Thorac Cardiovasc Surg 2008; 136: 108–116.CrossRefGoogle ScholarPubMed
4.d’Udekem, Y, Iyengar, AJ, Cochrane, AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation 2007; 116 Suppl. 11: I157–I164.CrossRefGoogle ScholarPubMed
5.Ghaferi, AA, Hutchins, GM. Progression of liver pathology in patients undergoing the Fontan procedure: chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg 2005; 129: 1348–1352.CrossRefGoogle ScholarPubMed
6.Kiesewetter, CH, Sheron, N, Vettukattill, JJ, et al. Hepatic changes in the failing Fontan circulation. Heart 2007; 93: 579–584.CrossRefGoogle ScholarPubMed
7.Camposilvan, S, Milanesi, O, Stellin, G, Pettenazzo, A, Zancan, L, D’Antiga, L. Liver and cardiac function in the long term after Fontan operation. Ann Thorac Surg 2008; 86: 177–182.CrossRefGoogle Scholar
8.Kendall, TJ, Stedman, B, Hacking, N, et al. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol 2008; 61: 504–508.CrossRefGoogle ScholarPubMed
9.Saliba, T, Dorkhom, S, O’Reilly, EM, Ludwig, E, Gansukh, B, Abou-Alfa, GK. Hepatocellular carcinoma in two patients with cardiac cirrhosis. Eur J Gastroenterol Hepatol 2010; 22: 889–891.CrossRefGoogle ScholarPubMed
10.Babaoglu, K, Binnetoglu, FK, Aydogan, A, et al. Hepatic adenomatosis in a 7-year-old child treated earlier with a Fontan procedure. Pediatr Cardiol 2010; 31: 861–864.CrossRefGoogle Scholar
11.Zhou, K, Gao, CF, Zhao, YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010; 25: 1569–1577.CrossRefGoogle ScholarPubMed
12.Imbert-Bismut, F, Ratziu, V, Pieroni, L, Charlotte, F, Benhamou, Y, Poynard, T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069–1075.Google Scholar
13.Cales, P, Oberti, F, Michalak, S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373–1381.CrossRefGoogle ScholarPubMed
14.Lebray, P, Varnous, S, Charlotte, F, Varaut, A, Poynard, T, Ratziu, V. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology 2008; 48: 2089.CrossRefGoogle ScholarPubMed
15.Sandrin, L, Fourquet, B, Hasquenoph, JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705–1713.CrossRefGoogle ScholarPubMed
16.Millonig, G, Friedrich, S, Adolf, S, et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52: 206–210.Google Scholar
17.Jarcuska, P, Janicko, M, Veseliny, E, Skladany, L. Circulating markers of liver fibrosis progression. Clin Chim Acta 2010; 411: 1009–1017.CrossRefGoogle ScholarPubMed
18.Goyal, N, Jain, N, Rachapalli, V, Cochlin, DL, Robinson, M. Non-invasive evaluation of liver cirrhosis using ultrasound. Clin Radiol 2009; 64: 1056–1066.CrossRefGoogle ScholarPubMed
19.Huwart, L, Sempoux, C, Vicaut, E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32–40.CrossRefGoogle ScholarPubMed
20.Bridges, ND, Lock, JE, Mayer, JE Jr, Burnett, J, Castaneda, AR. Cardiac catheterization and test occlusion of the interatrial communication after the fenestrated Fontan operation. J Am Coll Cardiol 1995; 25: 1712–1717.CrossRefGoogle ScholarPubMed
21.Reinhardt, Z, Uzun, O, Bhole, V, et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young 2010; 20: 522–525.CrossRefGoogle ScholarPubMed
22.Giardini, A, Balducci, A, Specchia, S, Gargiulo, G, Bonvicini, M, Picchio, FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008; 29: 1681–1687.Google Scholar
23.Jahangiri, M, Kreutzer, J, Zurakowski, D, Bacha, E, Jonas, RA. Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. J Thorac Cardiovasc Surg 2000; 120: 778–782.Google Scholar
24.Odegard, KC, McGowan, FX Jr, Zurakowski, D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 2003; 125: 1260–1267.CrossRefGoogle ScholarPubMed
25.Raffini, L, Schwed, A, Zheng, XL, et al. Thromboelastography of patients after Fontan compared with healthy children. Pediatr Cardiol 2009; 30: 771–776.CrossRefGoogle ScholarPubMed
26.Coon, PD, Rychik, J, Novello, RT, Ro, PS, Gaynor, JW, Spray, TL. Thrombus formation after the Fontan operation. Ann Thorac Surg 2001; 71: 1990–1994.Google Scholar
27.Jacobs, ML, Pourmoghadam, KK, Geary, EM, et al. Fontan’s operation: is aspirin enough? Is coumadin too much? Ann Thorac Surg 2002; 73: 64–68.CrossRefGoogle ScholarPubMed
28.Mahnke, CB, Boyle, GJ, Janosky, JE, Siewers, RD, Pigula, FA. Anticoagulation and incidence of late cerebrovascular accidents following the Fontan procedure. Pediatr Cardiol 2005; 26: 56–61.Google Scholar
29.Rychik, J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007; 2: 288–300.CrossRefGoogle ScholarPubMed
30.Mertens, L, Hagler, DJ, Sauer, U, Somerville, J, Gewillig, M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998; 115: 1063–1073.Google Scholar
31.Rychik, J. Forty years of the Fontan operation: a failed strategy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2010; 13: 96–100.CrossRefGoogle ScholarPubMed
32.Gewillig, M, Brown, SC, Eyskens, B, et al. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg 2010; 10: 428–433.CrossRefGoogle ScholarPubMed
33.Rychik, J, Gui-Yang, S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002; 90: 672–674.CrossRefGoogle ScholarPubMed
34.Uzun, O, Wong, JK, Bhole, V, Stumper, O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006; 82: e39–e40.CrossRefGoogle ScholarPubMed
35.Ostrow, AM, Freeze, H, Rychik, J. Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006; 82: 695–700.CrossRefGoogle ScholarPubMed
36.Lenz, D, Hambsch, J, Schneider, P, et al. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 2003; 7: 185–190.CrossRefGoogle ScholarPubMed
37.Cohen, MI, Rhodes, LA, Wernovsky, G, Gaynor, JW, Spray, TL, Rychik, J. Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 2001; 121: 582–583.Google Scholar
38.Mertens, L, Dumoulin, M, Gewillig, M. Effect of percutaneous fenestration of the atrial septum on protein-losing enteropathy after the Fontan operation. Br Heart J 1994; 72: 591–592.Google Scholar
39.Rychik, J, Rome, JJ, Jacobs, ML. Late surgical fenestration for complications after the Fontan operation. Circulation 1997; 96: 33–36.Google Scholar
40.Donnelly, JP, Rosenthal, A, Castle, VP, Holmes, RD. Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation. J Pediatr 1997; 130: 474–478.Google Scholar
41.Rychik, J, Piccoli, DA, Barber, G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991; 68: 819–821.Google Scholar
42.Thacker, D, Patel, A, Dodds, K, Goldberg, DJ, Semeao, E, Rychik, J. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010; 89: 837–842.Google Scholar
43.Costello, JM, Steinhorn, D, McColley, S, Gerber, ME, Kumar, SP. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics 2002; 109: e67.CrossRefGoogle Scholar
44.DiCindio, S, Theroux, M, Costarino, AT Jr, Cook, S, O’Reilly, R. Plastic bronchitis: a case report. Paediatr Anaesth 2004; 14: 520–523.Google Scholar
45.Apostolopoulou, SC, Papagiannis, J, Rammos, S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005; 24: 1174–1176.Google Scholar
46.Onoue, Y, Adachi, Y, Ichida, F, Miyawaki, T. Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. Pediatr Int 2003; 45: 107–109.CrossRefGoogle Scholar
47.Wilson, J, Russell, J, Williams, W, Benson, L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol 2005; 26: 717–719.Google Scholar
48.Ishman, S, Book, DT, Conley, SF, Kerschner, JE. Plastic bronchitis: an unusual bronchoscopic challenge associated with congenital heart disease repair. Int J Pediatr Otorhinolaryngol 2003; 67: 543–548.Google Scholar
49.Zaccagni, HJ, Kirchner, L, Brownlee, J, Bloom, K. A case of plastic bronchitis presenting 9 years after Fontan. Pediatr Cardiol 2008; 29: 157–159.CrossRefGoogle ScholarPubMed
50.Do, TB, Chu, JM, Berdjis, F, Anas, NG. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol 2009; 30: 352–355.Google Scholar
51.Wakeham, MK, Van Bergen, AH, Torero, LE, Akhter, J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. Pediatr Crit Care Med 2005; 6: 76–78.CrossRefGoogle Scholar
52.Rodefeld, MD, Coats, B, Fisher, T, et al. Cavopulmonary assist for the univentricular Fontan circulation: von Karman viscous impeller pump. J Thorac Cardiovasc Surg 2010; 140: 529–536.CrossRefGoogle Scholar
53.Bhavsar, SS, Kapadia, JY, Chopski, SG, Throckmorton, AL. Intravascular mechanical cavopulmonary assistance for patients with failing Fontan physiology. Artif Organs 2009; 33: 977–987.Google Scholar